Phathom Pharmaceuticals, Inc. PHAT
Updated: 18 Jun 2026
No signal published yet
We already track Phathom Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Phathom Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Phathom Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On April 30, 2026, the company reported Q1 revenue of $58.3 million, a 104% increase year-over-year, driven by strong VOQUEZNA prescription growth. Management reiterated guidance for achieving operating profitability by the third quarter of 2026.
What Firelda Watch includes for Phathom Pharmaceuticals, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Phathom Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Phathom Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more